Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812925 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
A Phase 3 study of Primary Immune Thrombocytopenia, sponsored by argenx.
- Active
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT04812925: Active Phase 3 study of Primary Immune Thrombocytopenia, sponsored by argenx.
NCT04812925 is a Phase 3 study of Primary Immune Thrombocytopenia that is active but no longer recruiting, run by argenx. The registered enrollment target is 173 participants, above the 96-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04812925, a Phase 3 study of Primary Immune Thrombocytopenia, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
Conditions Studied
Interventions
- BIOLOGICAL efgartigimod PH20 SC
Study Locations (20)
Other
- Investigator Site 0540001 - Buenos Aires
- Investigator site 540004 - Buenos Aires
- Investigator Site 0610012 - Garran
- Investigator Site 0610003 - West Perth
- Investigator site 610005 - Westmead
- Investigator Site 3590017 - Plovdiv
- Investigator site 0560003 - Reñaca
- Investigator site 560002 - Santiago
- Investigator site 0560004 - Temuco
- Investigator site 860013 - Beijing
- Investigator Site 0860008 - Bengbu
- Investigator site 860055 - Huizhou
- Investigator Site 0860015 - Shenzhen
- Investigator Site 0860001 - Tianjin
- Investigator Site 0860010 - Wuhan
Arkansas
- Investigator Site 0010116 - Bentonville
District of Columbia
- Investigator site 0010045 - Washington D.C.
Indiana
- Investigator Site 0010062 - Fort Wayne
Iowa
- Investigator site US0010042 - Iowa City
Oklahoma
- Investigator Site 0010095 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 3 |
What the registry record for NCT04812925 still lists
NCT04812925 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 96-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (80% higher).
The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which efgartigimod PH20 SC is the first listed.
NCT04812925 names 20 study sites across 6 states, led by Other, Arkansas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04812925 about?
NCT04812925 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia". A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
What is the current status of trial NCT04812925?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2021-11-17. Estimated completion is 2026-10-01.
What conditions does trial NCT04812925 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia.
What interventions are being tested in trial NCT04812925?
The interventions under investigation include: efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04812925?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04812925 being conducted?
This trial has 20 study locations across Arkansas, District of Columbia, Indiana, Iowa, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
COMPLETED · Phase 3
-
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
RECRUITING · Phase 2
-
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI